Leqvio
News/ News/ Sales and Marketing
Novartis bags elusive US approval for cholesterol drug inclisiran
Phil Taylor
Amgen, cholesterol, inclisiran, Leqvio, Novartis, PCSK9, Praluent, Regeneron, regulatory approval, Repatha, Sanofi
0 Comment
NICE backs NHS use of Novartis’ cholesterol drug Leqvio
Phil Taylor
cholesterol, gene silencing, HEOR, inclisiran, Leqvio, market access, NHS, NICE, Novartis, RNAi
0 Comment
Novartis eyes New Year verdict from FDA on delayed Leqvio
Phil Taylor
asciminib, cholesterol, fda, Leqvio, Novartis
0 Comment
Novartis’ big bet on inclisiran nears fruition, as CHMP backs drug
Phil Taylor
cardiovascular disease, CHMP, cholesterol, ema, inclisiran, Leqvio, Novartis
0 Comment